CervoMed FY2024 EPS Boosted by Brookline Capital Management

CervoMed Inc. (NASDAQ:CRVO) – Analysts at Brookline Capital Management raised their FY2024 earnings per share (EPS) estimates for shares of CervoMed in a research note issued to investors on Tuesday, March 11th. Brookline Capital Management analyst T. Bussian now anticipates that the company will post earnings of ($1.80) per share for the year, up from their prior forecast of ($1.88). Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed’s Q4 2024 earnings at ($0.70) EPS, Q1 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.39) EPS and FY2025 earnings at ($1.71) EPS.

A number of other research analysts have also issued reports on CRVO. HC Wainwright lowered CervoMed from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 17th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of CervoMed in a research report on Tuesday. Morgan Stanley reiterated an “underweight” rating on shares of CervoMed in a research report on Wednesday, December 11th. Roth Capital upgraded CervoMed to a “strong-buy” rating in a research report on Thursday, December 5th. Finally, Canaccord Genuity Group reduced their price target on CervoMed from $65.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.14.

CervoMed Stock Performance

NASDAQ:CRVO opened at $6.17 on Thursday. CervoMed has a 12-month low of $1.80 and a 12-month high of $26.38. The business has a 50 day simple moving average of $2.30 and a 200 day simple moving average of $8.20.

Institutional Trading of CervoMed

Hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in shares of CervoMed in the 4th quarter worth $26,000. DRW Securities LLC bought a new stake in shares of CervoMed in the 4th quarter worth $30,000. Mariner LLC bought a new stake in shares of CervoMed in the 4th quarter worth $30,000. BNP Paribas Financial Markets bought a new stake in shares of CervoMed in the 4th quarter worth $32,000. Finally, JPMorgan Chase & Co. raised its stake in shares of CervoMed by 251.8% in the 4th quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock worth $34,000 after buying an additional 10,352 shares in the last quarter. Institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.